Enzymatica publishes prospectus
in or into the United States, Australia, Japan, Canada, Hong Kong, New Zeeland,
Singapore or South Africa or any other jurisdiction where such action is subject
to legal restrictions.
This press release may not be published or distributed, directly or indirectly, in or into the United States, Australia, Japan, Canada, Hong Kong, New Zeeland, Singapore or South Africa or any other jurisdiction where such action is subject to legal restrictions.
Enzymatica announces today that the prospectus for the rights issue, approved by the Extraordinary General Meeting on April 14, has been approved by the Swedish Financial Supervisory Authority and is now available of Enzymatica's web site, www.enzymatica.com.
The prospectus including information and instructions on how to participate in the rights issue has been made available on Enzymatica's web site, www.enzymatica.se.
Shareholders whose holdings are directly registered in Euroclear Sweden AB on the record date April 19, 2016 will receive a printed issue statement including an application form. Shareholders whose holdings are in a nominee bank or other nominee will not receive a printed issue statement. Subscription and payment for new shares subscribed for through subscription rights is made through the respective nominee in accordance with the instructions from such nominee, or if the holdings are registered with several nominees, from each nominee respectively.
The subscription period runs from 21 April to 6 May 2016. Those who hold shares in Enzymatica on the record date will receive one (1) subscription right per share and five (5) subscription rights entitle to subscribe for three (3) new shares in the company at a price of SEK 2.18 per share. In addition, shareholders and other investors are invited to subscribe for shares without preferential right. The rights issue is fully secured through guarantees and subscription commitments.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: email@example.com
Carl-Johan Wachtmeister, deputy communication officer Enzymatica
Tel: 0701-88 50 21 | E-post: firstname.lastname@example.org
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.
Enzymatica's certified advisor is Erik Penser Bankaktiebolag.
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Enzymatica AB (publ). Any invitation to the persons concerned to subscribe for shares in Enzymatica AB (publ) will only be made through the prospectus that Enzymatica AB (publ) estimates to publish on or about 20 April 2016.
This press release may not be published or distributed, directly or indirectly in or into the United States, Australia, Japan, Canada, Hong Kong, New Zeeland, Singapore or South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or would require such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.
No subscription rights, interim shares or new shares have been registered, and will not be registered, under the United States Securities Act of 1933 ("Securities Act") or securities legislation in any other state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly within the United States, other than pursuant to an exemption from the registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.
This press release may contain forward-looking statements which reflect Enzymatica AB (publ):s current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the real outcome could differ materially from the forward-looking statements.